NASDAQ: LTRNLantern Pharma Inc Stock
$3.97-0.05 (-1.24%)
Updated Jul 2, 2026
LTRN Price
$3.97
Fair Value Price
N/A
Market Cap
$44.88M
52 Week Low
$1.11
52 Week High
$5.74
P/E
-2.74x
P/B
13.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.1
Operating Cash Flow
-$15M
Beta
1.39
Next Earnings
Aug 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LTRN Overview
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LTRN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LTRN
Ranked#134 of 463
Ranked#134 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important LTRN news, forecast changes, insider trades & much more!
LTRN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LTRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LTRN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LTRN is poor value based on its book value relative to its share price (13.02x), compared to the US Biotechnology industry average (5.6x)
P/B vs Industry Valuation
LTRN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LTRN due diligence checks available for Premium users.
Valuation
LTRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.74x
Industry
17.59x
Market
8.54x
LTRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.02x
Industry
5.6x
LTRN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LTRN's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
LTRN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.2M
Liabilities
$3.8M
Debt to equity
1.1
LTRN's short-term assets ($7.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LTRN's short-term assets ($7.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LTRN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LTRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
$4.3M
Financing
$0.0
LTRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LTRN vs Biotech Stocks
Lantern Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.